Systematically review of modified Sanzi Yangqin Decoction for treating acute exacerbation of chronic obstructive pulmonary disease.
10.19540/j.cnki.cjcmm.20190122.001
- Author:
Wen-Jiang ZHENG
1
;
Zi-Jing PENG
1
;
Shu-Wan CHEN
1
;
Yu HONG
2
;
Hui-Ting HUANG
2
;
Hui-Li LIAO
2
;
Xiao-Hong LIU
2
Author Information
1. the First Clinical College,Guangzhou University of Chinese Medicine Guangzhou 510405,China.
2. the First Affiliated Hospital,Guangzhou University of Chinese Medicine Guangzhou 510405,China.
- Publication Type:Journal Article
- Keywords:
Sanzi Yangqin Decoction;
acute exacerbation;
chronic obstructive pulmonary disease;
modified;
systematic review;
trial sequential analysis
- MeSH:
Drugs, Chinese Herbal;
therapeutic use;
Forced Expiratory Volume;
Humans;
Lung;
Pulmonary Disease, Chronic Obstructive;
drug therapy;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2019;44(10):2171-2178
- CountryChina
- Language:Chinese
-
Abstract:
The randomized controlled trials( RCTs) about modified Sanzi Yangqin Decoction in the treatment of patients with exacerbation of chronic obstructive pulmonary disease( AECOPD) were collected from 7 databases( PubMed,CNKI,etc.) till December25,2018 from their inception. All the studies searched were strictly evaluated and independently screened by two researchers according to the inclusion and exclusion criteria,and the methodological quality of included studies was evaluated. In order to systematically review the efficacy and safety of modified Sanzi Yangqin Decoction for treating AECOPD,the Meta-analysis and trial sequential analysis were conducted by using Stata/SE 14. 0 and TSA 0. 9. 5. 10 Beta,respectively. A total of 22 RCTs involving 2 012 patients were included. The results of Meta-analysis suggested that: as compared with the control group,the clinical symptoms in AECOPD patients were improved( RR = 1. 19,95%CI[1. 15,1. 24],P = 0); the pulmonary functions including forced expiratory volume in one second( FEV_1)( SMD= 0. 96,95%CI[0. 39,1. 52],P= 0. 001),the percentage of forced expiratory volume in one second( FEV_1%)( SMD =0. 80,95%CI[0. 20,1. 41],P = 0. 009),forced vital capacity( FVC)( SMD = 0. 69,95% CI[0. 06,1. 31],P = 0. 032),first seconds breathing volume percentage of forced vital capacity( FEV_1/FVC) were improved( SMD = 0. 81,95%CI[0. 64,0. 97],P = 0);the arterial oxygen partial pressure( PaO_2) was improved( SMD= 0. 87,95%CI[0. 41,1. 32],P= 0); the arterial partial pressure of carbon dioxide( PaCO_2) was decreased( SMD =-0. 91,95%CI[-1. 33,-0. 49],P = 0) in the trial group. In addition,the incidence of adverse reactions in the experimental group was low,and there were no serious adverse events. The trial sequential analysis( TSA) showed that the studies included in the improvement of clinical efficacy had passed the conventional and TSA threshold at the same time,further confirming the efficacy of trial group. This research showed that,conventional Western medicine treatment,combined with modified Sanzi Yangqin Decoction in treating acute exacerbation patients with chronic obstructive pulmonary disease could improve the clinical efficiency and pulmonary functions,improve the PaO_2,decrease the PaCO_2,with a high safety. However,the quality of existing research is low,requiring more high quality clinical trials for further validation.
